What is Delvitech?
Delvitech is a specialized life sciences instrumentation company focused on designing and manufacturing advanced analytical instruments for pharmaceutical and biotechnology quality control. Their core offering, the Delvi Diagnostics Platform, provides real-time measurement of critical quality attributes (CQAs) in drug products, such as protein aggregation, particle size distribution, and formulation stability. This technology empowers pharmaceutical manufacturers and contract development organizations (CDMOs) to conduct rapid, automated quality testing throughout the drug development and manufacturing lifecycle, aligning with the FDA's Process Analytical Technology (PAT) initiative. By integrating optical measurement techniques with automated sample handling and sophisticated data analytics, Delvitech enhances drug product quality and manufacturing efficiency.
How much funding has Delvitech raised?
Delvitech has raised a total of $40M across 1 funding round:
Series B
$40M
Series B (2025): $40M with participation from EGS Beteiligungen and CreAdd
Key Investors in Delvitech
EGS Beteiligungen
EGS Beteiligungen AG is a long-term investment firm focused on Swiss-related companies, with an interest in growth financing for late-stage technology startups. Their investment philosophy emphasizes capital preservation and sustainable profitability.
CreAdd
CreAdd is a content creation specialist that leverages visual media to build strong business brand identities. They focus on extracting a brand's essence and translating it into compelling visual narratives.
What's next for Delvitech?
With this substantial enterprise-level backing, Delvitech is poised for significant expansion and technological advancement. The major strategic investment signals strong confidence from investors in the company's innovative approach to drug quality control. This capital infusion will likely fuel further research and development, enhance manufacturing capabilities, and broaden market reach. The company's focus on supporting the FDA's PAT initiative positions it favorably within the evolving regulatory landscape, suggesting a strategic push towards wider adoption of its advanced analytical instruments in the pharmaceutical and biotechnology sectors.
See full Delvitech company page
